1
Clinical Trials associated with BCMA-CART(Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.)A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
100 Clinical Results associated with BCMA-CART(Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.)
100 Translational Medicine associated with BCMA-CART(Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.)
100 Patents (Medical) associated with BCMA-CART(Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.)
100 Deals associated with BCMA-CART(Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.)